These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 22850772)
1. PDUFA V goes back to basics. Mullard A Nat Rev Drug Discov; 2012 Aug; 11(8):586-8. PubMed ID: 22850772 [No Abstract] [Full Text] [Related]
2. Regulatory watch: impact of PDUFA on regulatory decision-making. Hay M Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755 [No Abstract] [Full Text] [Related]
3. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Zelenay JL Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773 [No Abstract] [Full Text] [Related]
4. PLIVA v. Mensing: generic consumers' unfortunate hand. Lee SB Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916 [No Abstract] [Full Text] [Related]
5. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
6. Recent developments help the defense of drug companies in 10b-5 cases. Salpeter AN; Hutchins H Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711 [No Abstract] [Full Text] [Related]
8. PDUFA reauthorization--drug safety's golden moment of opportunity? Hennessy S; Strom BL N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082 [No Abstract] [Full Text] [Related]
9. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
10. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
11. The FDA and "privatization"--the drug approval process. Rutherford EM Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044 [No Abstract] [Full Text] [Related]
12. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
13. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Thomson Reuters/West Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841 [No Abstract] [Full Text] [Related]
14. FDAMA 1997 Section 114: another look. Jackson J Value Health; 2009; 12(2):191-2. PubMed ID: 18657097 [No Abstract] [Full Text] [Related]
15. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
16. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
17. Teaching clinicians about drugs--50 years later, whose job is it? Avorn J N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781 [No Abstract] [Full Text] [Related]
19. Raising the bar for market authorisation of new drugs. Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693 [No Abstract] [Full Text] [Related]
20. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related] [Next] [New Search]